The Filing Desk

Cerenome vs DBV Technologies

Cerenome CNSY · DBV Technologies DBVT · Biotechnology

DBV Technologies reported revenue of $6 million in fiscal 2025, about the same as Cerenome's $5 million in fiscal 2025. Cerenome's revenue fell 10.5% in its latest year, and DBV Technologies' grew 35.8%. Cerenome had an operating margin of -293.5%, against -2609.2% at DBV Technologies. Free cash flow was −$21 million at Cerenome and −$122 million at DBV Technologies.

Side by side

CerenomeDBV Technologies
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$5M$6M
Revenue growth−10.5%35.8%
Revenue growth a year, last 5 years—−13.1%
Gross margin——
Operating margin−293.5%−2,609.2%
Net margin−429.4%−2,607.3%
Free cash flow−$21M−$122M
Free cash flow margin−399.8%−2,159.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count910.4%43.9%
Last close$0.70$9.42
P/E at the last close——
Insider trades, last 12 months—sold $15.5 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CerenomeDBV Technologies
Operating margin
Percent of revenue
CerenomeDBV Technologies
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CerenomeDBV Technologies

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cerenome and DBV Technologies pages.